Biotech Investment News: Novo Nordisk’s Major Deals from 2015 to 2025
Strategic Overview: Expanding from Diabetes to Obesity, RNA, and Cardiometabolic Disease Novo Nordisk, known for its leadership in GLP-1 receptor agonists (Ozempic, Wegovy), has expanded significantly over the past decade. Through acquis...
